Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 437 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia Patients Clear all
Completed Phase 4 Interventional Results available

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

NCT00190749
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Sep 3, 2026, 6:49 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

NCT00604760
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
MEM 3454, Placebo for MEM 3454
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
44
States / cities
Lemon Grove, California • Newport Beach, California • Oceanside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2008 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Not applicable Interventional

Medication Adherence in Older Adults With Serious Mental Illness

NCT00224380
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depression
Interventions
Using Medications Effectively
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Nashua, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 22, 2009 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of LY03010 Compared to Listed Drug

NCT04922593
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
Interventions
LY03010; paliperidone palmitate, INVEGA SUSTENNA
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

NCT00061802
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
risperidone, quetiapine
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
San Diego, California • Hoffman Est, Illinois • Lake Charles, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Not applicable Interventional

TEAMcare for Diabetes in Mental Health Centers

NCT02011529
View directory record Official record
Conditions
Diabetes
Interventions
TEAMcare treatment of diabetes
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 3, 2026, 6:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers

NCT00004571
View directory record Official record
Conditions
Schizophrenia, Normal Physiology
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 120 Years
Enrollment
3,273 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 3, 2026, 6:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuropsychological Evaluation of Psychiatric and Neurological Patients

NCT00001192
View directory record Official record
Conditions
Anxiety Disorder, Head Injury, Mood Disorder, Schizophrenia, Seizures
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Up to 95 Years
Enrollment
4,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1983 – 2006
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Not applicable Interventional Results available

A Brief Community Linkage Intervention for Dually Diagnosed Individuals

NCT00137267
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Substance-Related Disorders, Bipolar Disorder
Interventions
Time limited case management, Health Education
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Bedford, Massachusetts • East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Not applicable Interventional Results available

A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)

NCT00677898
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Patient-centered computerized tool, Written educational materials
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2015 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Results available

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

NCT00535145
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
Interventions
Treatment as usual (TAU), Paliperidone ER
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
21
States / cities
Cerritos, California • Chino, California • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Results available

A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

NCT00621777
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Bloomington, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Sep 3, 2026, 6:49 AM EDT
Terminated Phase 2 Interventional Results available

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

NCT03868839
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
Interventions
Telmisartan Pill
Drug
Lead sponsor
Xiaoduo Fan
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Not applicable Interventional

Reducing the Weight of Overweight Schizophrenia Patients

NCT00158366
View directory record Official record
Conditions
Schizophrenia, Obesity
Interventions
Behavioral training, Social skills training, Behavioral training booster sessions
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 60 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

NCT03943537
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
Interventions
Intranasal Insulin
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

NCT00615433
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 3, 2026, 6:49 AM EDT
Terminated Phase 2 Interventional Results available

Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome

NCT01127503
View directory record Official record
Conditions
Velo-cardio-facial Syndrome, Psychosis
Interventions
Metyrosine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Repetitive Transcranial Magnetic Stimulation for "Voices"

NCT00004980
View directory record Official record
Conditions
Schizophrenia
Interventions
repetitive transcranial magnetic stimulation (rTMS), sham stimulation
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 1 Interventional

Midazolam Drug-Drug Interaction Study With Lurasidone HCl

NCT01082263
View directory record Official record
Conditions
Schizophrenia Patients
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Not applicable Interventional

Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention

NCT00980252
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
16 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Not applicable Interventional

Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients

NCT00295139
View directory record Official record
Conditions
Schizophrenia, Mood Disorders, Substance Dependence
Interventions
Behavioral Treatment for Substance Abuse in SPMI (BTSAS), Supportive Treatment in Addiction Recovery (STAR), Critical Time Intervention (CTI)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Baltimore, Maryland • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Results available

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Bryant, Arkansas • Anaheim, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 3, 2026, 6:49 AM EDT
Completed Phase 3 Interventional Results available

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

NCT01432444
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole (Abilify®) IM Depot Injection
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
119
States / cities
Dothan, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 97 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 3, 2026, 6:49 AM EDT